Veozah (Fezolinetant) Reviews: Real User Efficacy Reports for Hot Flashes

What the Clinical Trials Actually Show

Fezolinetant 45 mg once daily produced a statistically significant reduction in moderate-to-severe vasomotor symptoms compared with placebo in SKYLIGHT-1, with the results published in The Lancet in 2023. The trial enrolled 501 postmenopausal women, and the 45 mg group saw mean hot flash frequency drop by approximately 60% from baseline at week 12.

SKYLIGHT-1 Key Numbers

In the SKYLIGHT-1 trial, women taking fezolinetant 45 mg experienced a mean reduction of 4.0 hot flashes per day at week 12 vs 2.5 in the placebo arm, a difference that was statistically significant (p <0.001). Severity scores (0-3 scale) also improved meaningfully. By week 1, fezolinetant already separated from placebo on frequency, which is faster than most women expect from a non-hormonal agent.

What "Significant Reduction" Means in Practice

A 60% reduction sounds large. But if you start at 10 severe hot flashes a day, a 60% drop leaves you at 4. Some women find 4 per day life-changing. Others find it still new enough to reconsider options. The trial data do not tell you which group you will fall into, and that is where real-user reports become genuinely useful.

The Evidence Gap for Perimenopause

SKYLIGHT-1 enrolled postmenopausal women. Fezolinetant has not been studied in women who are still menstruating with irregular cycles or in confirmed perimenopause. This is a real evidence gap. If you are perimenopausal and your clinician prescribes fezolinetant off-label, the efficacy data are being extrapolated, not directly applied.

How the NK3 Mechanism Explains Who It Helps Most

Fezolinetant blocks the neurokinin-3 (NK3) receptor in the hypothalamus. In postmenopausal women, falling estrogen levels increase kisspeptin-neurokinin B-dynorphin (KNDy) neuron firing, which drives thermoregulatory instability and the hot flash cascade. The Menopause Society (2023 position statement) identifies KNDy neuron overactivity as the central mechanism, and NK3 antagonism directly interrupts it without altering circulating estrogen.

Why This Matters for Women Who Cannot Take Hormones

Women with estrogen-receptor-positive breast cancer history, or those with a personal history of VTE who are not candidates for hormone therapy, have historically had limited options. Gabapentin and SSRIs/SNRIs carry their own side-effect burden. Fezolinetant gives this group a mechanistically targeted non-hormonal choice, and the user reviews from this population tend to be more positive precisely because the alternative bar is lower.

Why Some Women See Less Benefit

Not every postmenopausal hot flash is purely KNDy-driven. Women with thyroid dysfunction, adrenal causes, or medication-induced flushing (tamoxifen, for instance) may not see the same response, because the NK3 pathway is not the primary driver of their symptoms. Postpartum thyroiditis, which peaks 1 to 6 months after delivery, can also produce vasomotor symptoms, but fezolinetant is not studied in postpartum women.

What Real Women Report: Synthesizing User Reviews

Real-world user reviews of Veozah are available across Drugs.com, Reddit (primarily r/Menopause, r/Perimenopause, and r/HormoneTherapy), and PatientsLikeMe. These sources together represent a few hundred self-selected reporters as of early 2025. This is a small, self-selected sample with significant selection bias: women who seek out forums are more likely to be either very satisfied or very frustrated, and those who had no response may never post at all.

What Positive Reviewers Consistently Report

Women who rate Veozah highly share a few consistent themes:

• Hot flash frequency dropped noticeably in the first 1 to 2 weeks, which matches the clinical trial week-1 onset signal
• Night sweats improved before daytime hot flashes in some accounts, leading to better sleep quality within the first month
• The absence of hormones was specifically mentioned as important by women with cancer histories or who had previously experienced hormone-related side effects
• Several women described it as "the first thing that actually worked" after trying SSRIs and gabapentin

One pattern that appears in multiple Reddit threads in r/Menopause is women reporting they noticed a difference around day 10 to 14, then plateaued at a new, lower baseline rather than achieving complete elimination. That is consistent with the trial data showing partial, not complete, suppression.

What Negative or Mixed Reviewers Report

Women who rate Veozah poorly or stop the medication cite:

• Minimal or no change in hot flash frequency, even after 4 to 8 weeks
• Nausea in the first week, which resolved in most cases but led some to discontinue
• Abdominal discomfort and diarrhea, reported in the SKYLIGHT-1 trial at low rates and echoed in user reviews
• Cost and insurance coverage barriers causing discontinuation before adequate trial (most clinicians consider 8 to 12 weeks a fair assessment period)
• Disappointment when comparing to hormone therapy that a prior provider had prescribed before the woman became ineligible

The cost issue appears frequently in online forums and is worth naming plainly: Veozah's list price is approximately $550 to $600 per month without insurance coverage or a manufacturer savings card. Women without commercial insurance who rely on Medicare Part D may face substantial out-of-pocket costs, and several Reddit users described stopping the medication for financial rather than efficacy reasons. Cost is a real-world efficacy limitation that no clinical trial measures.

Forum-Specific Patterns

Across r/Menopause and r/Perimenopause threads, a consistent pattern emerges that is not captured in any published review or trial sub-analysis: women who combine Veozah with behavioral modifications (cooler sleeping environments, reduced alcohol, lower-carbohydrate evenings) report subjectively better outcomes than women using the medication alone. This is not a controlled observation, and selection bias almost certainly inflates the signal. Still, it suggests that clinicians who frame fezolinetant as one part of a broader symptom-management plan may set more realistic expectations than those who present it as a standalone fix.

The r/Perimenopause community also surfaces a recurring frustration: women with irregular cycles who cannot yet confirm menopause being told by their providers that Veozah is not FDA-approved for their stage, and feeling left without options. This is a gap the current indication does not address.

Pregnancy, Lactation, and Contraception: Required Reading

Fezolinetant is not approved or studied during pregnancy or breastfeeding. This section is not optional reading if you are not clearly postmenopausal.

Pregnancy

Fezolinetant has no pregnancy category under the current FDA labeling system (which replaced A/B/C/D/X with narrative risk summaries). The FDA prescribing information states that there are no adequate human data on use during pregnancy, and animal reproductive studies were conducted but do not reliably predict human risk. Based on the mechanism (NK3 receptor antagonism), potential effects on reproductive hormonal signaling cannot be excluded.

If you have not completed a full 12 months without a menstrual period, you may still be capable of ovulation. Fezolinetant does not contain hormones and provides no contraceptive protection. Women in early perimenopause prescribed this off-label must use a reliable method of contraception until menopause is confirmed.

Lactation

No data exist on fezolinetant transfer into human breast milk, effects on the breastfed infant, or effects on milk production. The FDA prescribing information advises that the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need and any potential infant risk. Given zero human lactation data, most clinicians would advise against use while breastfeeding.

What This Means by Life Stage

| Life stage | Fezolinetant status | |---|---| | Reproductive years (menstruating regularly) | Not studied; off-label; use contraception | | Trying to conceive | Avoid; no human safety data | | Pregnant | Avoid; no human safety data | | Postpartum / breastfeeding | Avoid; no lactation data | | Perimenopause (irregular cycles) | Off-label; pregnancy still possible; use contraception | | Confirmed menopause (12+ months amenorrhea) | FDA-approved indication |

Who This Is Right For and Who It Is Not

Understanding the right candidate for fezolinetant saves time, money, and frustration.

Likely Right For You

• You are confirmed postmenopausal (12+ months without a period, or surgical menopause)
• Moderate-to-severe hot flashes are disrupting sleep or daily function
• You cannot use systemic hormone therapy due to breast cancer history, VTE risk, or personal preference
• You have tried SSRIs, SNRIs, or gabapentin and found them poorly tolerated or ineffective
• You have normal liver function at baseline and can attend follow-up labs at 3 and 6 months
• Your insurance covers Veozah or you have access to the manufacturer savings program

Probably Not Right For You

• You have cirrhosis or severe hepatic impairment (contraindicated per FDA labeling)
• You take strong CYP1A2 inhibitors such as fluvoxamine (the drug interaction significantly raises fezolinetant exposure)
• Your vasomotor symptoms are mild and manageable without medication
• You are perimenopausal and still having regular or semi-regular cycles (off-label use, no efficacy data)
• Your hot flashes are driven by a non-menopausal cause (thyroid disease, carcinoid syndrome, medication side effects)

Liver Safety: The Monitoring Requirement Women Need to Know

Fezolinetant carries a labeled risk of drug-induced liver injury. In the SKYLIGHT-4 safety trial, hepatocellular injury (ALT more than 3 times the upper limit of normal) occurred in approximately 2.3% of fezolinetant users vs 0.7% of placebo users at 52 weeks. Most elevations were asymptomatic and resolved after discontinuation, but the signal is real.

What Monitoring Looks Like

Per FDA prescribing guidance, liver function tests are required:

• Before starting fezolinetant
• At 3 months
• At 6 months

If ALT or AST rises above 3 times the upper limit of normal, the medication should be stopped. This is a non-negotiable safety requirement, not a formality. Women who skip lab monitoring because they feel fine are taking an unquantified risk.

Many real-world reviews do not mention this at all, which suggests that either the monitoring is not being consistently communicated, or women do not connect liver labs to a drug they think of as "non-hormonal and therefore mild." The label's hepatotoxicity warning deserves more prominence in patient conversations.

Comparing Fezolinetant to Other Non-Hormonal Options

The Menopause Society 2023 nonhormone therapy position statement identifies the following as having the best evidence for non-hormonal vasomotor symptom management, in order of evidence quality:

1. Fezolinetant (the only FDA-approved non-hormonal agent specifically for VMS as of 2025)
2. Paroxetine 7.5 mg (Brisdelle, the only FDA-approved SSRI for VMS)
3. Venlafaxine 37.5 to 75 mg (evidence-based off-label)
4. Gabapentin 300 mg three times daily (off-label; evidence weaker)
5. Oxybutynin (emerging evidence; off-label)

Fezolinetant's specific advantage is mechanism: it targets the cause of menopausal hot flashes (KNDy neuron overactivity) rather than modulating serotonin or GABA pathways as a secondary effect. In head-to-head patient experience, women who have already tried SSRIs or gabapentin and found them inadequate represent the clearest group where fezolinetant offers something genuinely different.

The Hormone Therapy Comparison Question

Women frequently ask, in online forums, how Veozah compares to hormone therapy (HT). This is the honest answer: HT (estradiol with or without progestogen) remains more effective for most postmenopausal women who are candidates. A 2022 Cochrane review of hormone therapy for menopausal symptoms found that combined HRT reduced hot flash frequency by approximately 75% compared with placebo, larger than the roughly 60% seen with fezolinetant. Fezolinetant is the right choice when HT is contraindicated or declined, not automatically the first choice for every postmenopausal woman.

Onset, Duration, and What to Tell Your Clinician at Follow-Up

Most women who respond to fezolinetant notice a difference within the first 1 to 2 weeks. In the SKYLIGHT-1 trial, statistically significant separation from placebo was seen at week 1 for frequency and at week 4 for severity. If you have had no change whatsoever at 4 weeks, that is worth reporting to your clinician.

Setting a Realistic 8-Week Check-In

At 8 weeks, ask yourself and your provider:

• Has hot flash frequency dropped by at least 30 to 40%? (Below 30% reduction suggests poor response)
• Has sleep quality improved at least somewhat?
• Are side effects (especially GI symptoms) manageable or resolved?
• Are liver labs due at the 3-month mark scheduled?

If the answer to the first two questions is no at 8 weeks, the evidence for continued benefit is thin. Continuing past 12 weeks without meaningful response is not supported by trial data.

What the Trial Did Not Measure

SKYLIGHT-1 did not assess brain fog, joint pain, vaginal dryness, or mood. These are common menopausal complaints. Fezolinetant addresses vasomotor symptoms only. Women who expect broader menopause symptom relief will likely be disappointed, and user reviews that express this disappointment are not indicating that the drug failed at its actual indication.

The PCOS and Perimenopause Considerations

Women with PCOS who are approaching perimenopause represent a specific subgroup where fezolinetant raises interesting questions. PCOS is associated with altered KNDy neuron signaling, and some research suggests elevated neurokinin B contributes to the LH pulse dysregulation seen in PCOS. A small study in PCOS found that NK3 receptor antagonism reduced LH pulse frequency, pointing to a potential reproductive endocrine effect. This is not a reason to use fezolinetant in premenopausal PCOS management: the drug is not approved for that indication, and the reproductive consequences of NK3 antagonism in women who are still cycling are not established. Women with PCOS considering fezolinetant in perimenopause should have this conversation explicitly with a reproductive endocrinologist or menopause specialist.

Practical Tips From Women Who Have Used It

Synthesizing across forum posts, the following practical points appear repeatedly in accounts from women who stayed on fezolinetant long enough to assess it:

• Take it at the same time each day. Several users noted more consistent symptom control with a fixed morning dose vs forgetting and catching up at night.
• GI side effects in the first 1 to 2 weeks were more common in women who took it on an empty stomach.
• Do not skip the 3-month liver labs. This appears repeatedly in advice from users who were warned by their providers.
• Keep a symptom diary for the first 4 weeks. Women who tracked hot flash frequency objectively reported feeling more confident in their assessment of whether the drug was working, compared with women who relied on memory.
• Cost assistance: AstraZeneca's savings card program brought out-of-pocket cost to as low as $0 for some commercially insured women in 2024. The program is worth checking before abandoning the medication for financial reasons.